Proteomic analysis of bladder cancer by iTRAQ after Bifidobacterium infantis-mediated HSV-TK/GCV suicide gene treatment

Biological Chemistry

Volumn 394, Issue 10, 2013, Pages 1333-1342

  Jiang, Li ^a   Ren, Jin ^a   Xiao, Xiao ^a   Tang, Yong Yong ^a   Weng, Hong Qing ^a   Yang, Qi ^a   Wu, Ming Jun ^a   Tang, Wei ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

BI TK GCV; Bladder cancer; ITRAQ; Mass spectrometry; Proteomics

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ANTINEOPLASTIC AGENT; CD146 ANTIGEN; CELL SURFACE PROTEIN; CYCLINE; HERPES SIMPLEX VIRUS THYMIDINE KINASE GANCICLOVIR; HEXOKINASE 1; PYRUVATE KINASE; PYRUVATE KINASE ISOZYME M2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIFIDOBACTERIUM LONGUM INFANTIS; BLADDER CANCER; CANCER GROWTH; DOWN REGULATION; FEMALE; GENE CONSTRUCT; GLYCOLYSIS; IMMUNOHISTOCHEMISTRY; ISOBARIC TAGS FOR RELATIVE AND ABSOLUTE QUANTIFICATION; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; RAT; SUICIDE GENE; SUICIDE GENE THERAPY; TANDEM MASS SPECTROMETRY; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BIFIDOBACTERIUM; BLOTTING, WESTERN; COMPUTATIONAL BIOLOGY; GANCICLOVIR; GENE EXPRESSION REGULATION; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; IMMUNOHISTOCHEMISTRY; PROTEOMICS; RATS; RATS, SPRAGUE-DAWLEY; SIMPLEXVIRUS; URINARY BLADDER NEOPLASMS;

EID: 84888111029     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2013-0201     Document Type: Article

References (36)

1. Als, AB., Dyrskjøt, L., von der Maase, H., Koed, K., Mansilla, F., Toldbod, H.E., Jensen, J.L., Ulhøi, B.P., Sengeløv, L., Jensen, K.M, et al. (2007). Emmprin and surviving predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin. Cancer Res. 13, 4407-4414. (Pubitemid 47219707)
2. Ardelt, P. and Bohle, A. (2002). Molecular aspects of bladder cancer I V: gene therapy of bladder cancer. Eur. Urol. 41, 372-381. (Pubitemid 35333931)
3. Brown, J.M. and Wilson, W.R. (2004). Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437-447. (Pubitemid 38745529)
4. Cavallaro, U. and Christofori, G. (2005). Cell adhesion and signaling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 4, 118-132.
5. Christofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten, R.E., Wei, R., Fleming, M.D., Schreiber, S.L., and Cantley, L.C. (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233. (Pubitemid 351380249)
6. de Braud, F., Maffezzini, M., Vitale, V., Bruzzi, P., Gatta, G., Hendry, W.F., and Sternberg, C.N. (2002). Bladder cancer. Crit. Rev. Oncol. Hematol. 41, 89.
7. Gerschwind, J.F., Georgiades, C.S., Ko, Y.H., and Pedersen, P.L. (2002). Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res. 62, 3909-3913. (Pubitemid 34791050)
8. Godoy, P., Lakkapamu, S., Schug, M., Bauer, A., Stewart, J.D., Bedawi, E., Hammad, S., Amin, J., Marchan, R., Schormann, W, et al. (2010). Dexamethasone-dependent versus -independent markers of epithelial to mesenchymal transition in primary hepatocytes. Biol. Chem. 391, 73-83.
9. Greenlee, R.T., Hill-Harmon, M.B., Murray, T., and Thun, M. (2001). Cancer statistics, 2001. CA Cancer J. Clin. 51, 15.
10. Hattori, K., Uchida, K., Akaza, H., Koiso, K., Nemoto, R., and Harada, M. (1995). Proliferating cell nuclear antigen cyclin in human transitional cell carcinoma. Br. J. Urol. 75, 162-166.
11. Hindges, R. and Hübscher, U. (1997). DNA polymerase delta, an essential enzyme for DNA transactions. Biol. Chem. 378, 345-362. (Pubitemid 27267576)
12. Jones, R.G., Plas, D.R., Kubek, S., Buzzai M., Mu, J., and Xu, Y. (2005). AMP-activated protein kinase induces a p53-dependent metabolic switch. Mol. Cell. 18, 283-293. (Pubitemid 41350534)
13. Kaufman, D.S., Shipley, W.U., and Feldman, A.S. (2009). Bladder cancer. Lancet 374, 239-249.
14. Kimura, N.T., Taniguchi, S., Aoki, K., and Baba, T. (1980). Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res. 40, 2061-2068. (Pubitemid 10116138)
15. Ko, Y.H., Pederson, P.L., and Gerschwind, J.F. (2001). Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett. 173, 83-91. (Pubitemid 32907513)
16. Ko, Y.H., Smith, B.L., Wang, Y., Pomper, M.G., Rini, D.A., and Torbenson, M.S. (2004). Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res. Commun. 3, 269-275. (Pubitemid 39311489)
17. Kristiansen, G., Yu, Y., Schlüns, K., Sers, C., Dietel, M., and Petersen, I. (2003). Express ion of the cell adhesion molecule CD146 /MCAM in non-sm all cell lung cancer. Anal. Cell. Pathol. 25, 77-81. (Pubitemid 36443407)
18. Krüger, S. and Müller, H. (1995). Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas. Br. J. Urol. 75, 480-484.
19. Lavezzi, A.M., Biondo, B., Cazzullo, A., Giordano, F., Pallotti, F., Turconi, P., and Matturri, L. (2001). The role of different biomarkers (DNA, PCNA, apoptosis and karyotype) in prognostic evaluation of superficial transitional cell bladder carcinoma. Anticancer Res. 21, 1279-1284. (Pubitemid 32494133)
20. Li, X., Fu, G.F., Fan, Y.R., Liu, W.H., Liu, X.J., Wang, J.J., and Xu, G.X. (2003). Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 10, 105-111. (Pubitemid 36228257)
21. Nishishita, T. and Lin, P.C. (2004). Angiopoietin 1, PDGF-B, and TGF-beta gene regulation in endothelial cell and smooth muscle cell interaction. J. Cell. Biochem. 91, 584-593.
22. Omar, H.A., Salama, S.A., Arafa, el-SA., and Weng, J.R. (2013). Antitumor effects of energy restriction-mimetic agents: thiazolidinediones. Biol. Chem. 394, 865-870.
23. Pan, J.G., Zhou, X., Zeng, G.W., and Han, R.F. (2012). Potent antitumour activity of the combination of HSV-TK and endostatin armed oncolytic adeno-associated virus for bladder cancer in vitro and in vivo. J. Surg. Oncol. 105, 249-257.
24. Park, J., Ha, H., Kim, M.S., Ahn, H.J., Huh, K.H., and Kim, Y.S. (2006). Carvedilol inhibits platelet-derived growth factorinduced extracellular matrix synthesis by inhibiting cellular reactive oxygen species and mitogen-activated protein kinase activation. J. Heart Lung Transplant. 25, 683-689. (Pubitemid 43766584)
25. Sharma, A., Tandon, M., Bangari, D.S., and Mittal, S.K. (2009). Adenoviral vector-based strategies for cancer therapy. Curr Drug Ther. 4, 117-138.
26. Spoden, G.A., Mazurek, S., Morandell, D., Bacher, N., Ausserlechner, M.J., Jansen-Dürr, P., Eigenbrodt, E., and Zwerschke, W. (2008). Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int. J. Cancer 123, 312-321. (Pubitemid 351842015)
27. Takata, R., Katagiri, T., Kanehira, M., Tsunoda, T., Shuin, T., Miki, T., Namiki, M., Kohri, K., Matsushita, Y., Fujioka, T, et al. (2005). Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin. Cancer Res. 11, 2625-2636. (Pubitemid 40569463)
28. Terao, S., Shirakawa, T., Goda, K., Kamidono, S., Fujisawa, M., and Gotoh, A. (2005). Recombinant interleukin-2 enhanced the antitumor effect of ADV/RSV-HSV-tk/ACV therapy in a murine bladder cancer model. Anticancer Res. 25, 2757-2760. (Pubitemid 41044657)
29. Wu, G.J. (2005). METCAM/MUC18 expression and cancer metastasis. Curr. Genomics 6, 333-349.
30. Wu, G.J., Peng, Q., Fu, P., Wang, S.W., Chiang, C.F, Dillehay, D.L., and Wu, M.W. (2004). Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells. Gene 327, 201-213. (Pubitemid 38230115)
31. Xie, S., Luca, M., Huang, S., Gutman, M., Reich, R., Johnson, J.P., and Bar-Eli, M. (1997). Expression of MCAM/MCU18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res. 57, 2295-2303. (Pubitemid 27247052)
32. Yasui, H. and Ohwaki, M. (1991). Enhancement of immune response in Peyer's patch cells cultured with Bifidobacterium breve. J. Dairy Sci. 74, 1187-1195.
33. Yazawa, K., Fujimori, M., Amano, J., Kano, Y., and Taniguchi, S. (2000). Bifidobacterium longum as a delivery system for cancer gene therapy: selective location and growth in hypoxic tumors. Cancer Gene Ther. 7, 269-274. (Pubitemid 30194562)
34. Yi, W., Clark, P.M., Mason, D.E., Keenan, M.C., Hill, C., Goddard, W.A., III, Peters, E.C, Driggers, E.M., and Hsieh-Wilson, L.C. (2012). Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 337, 975-980.
35. Yin, X., Yu, B., Tang, Z., He, B., Ren, J., Xiao, X., and Tang, W. (2013). Bifidobacterium infantis-mediated HSV-TK/GCV suicide gene therapy induces both extrinsic and intrinsic apoptosis in a rat model of bladder cancer. Cancer Gene Ther. 20, 77-81.
36. Zabouo, G., Imbert, A.M., Jacquemier, J., Finetti, P., Moreau T., Esterni, B., Birnbaum, D., Bertucci, F., and Chabannon, C. (2009). CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res. 11, R1.